Document Detail


Coronary hyperemic dose responses of intracoronary sodium nitroprusside.
MedLine Citation:
PMID:  14993141     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Sodium nitroprusside is one of several agents considered effective for treating the no-reflow phenomenon during acute coronary interventions. However, the coronary hyperemic dose responses and systemic hemodynamic effects of intracoronary nitroprusside have yet to be determined in humans. The purpose of this study was to compare the hyperemic and hemodynamic responses of intracoronary nitroprusside to intracoronary adenosine in patients during cardiac catheterization with angiographically normal anterior descending arteries. METHODS AND RESULTS: In 21 patients, coronary blood flow velocity (0.014-inch Doppler flow wire), heart rate, and blood pressure were measured in unobstructed left anterior descending coronary arteries at rest, after intracoronary adenosine (30- to 50-microg boluses), and after 3 serial doses (0.3-, 0.6-, and 0.9-microg/kg boluses) of intracoronary nitroprusside. Coronary reserve was calculated as hyperemia/basal coronary flow velocity. In an additional 9 patients with intermediate stenoses (53+/-7%), 14 fractional flow reserve (FFR) measurements (using 0.014-inch pressure wire) were performed with both intracoronary adenosine and nitroprusside (0.6 microg/kg). Intracoronary nitroprusside produced equivalent coronary hyperemia with a longer duration ( approximately 25%) compared with intracoronary adenosine. Intracoronary nitroprusside (0.9 microg/kg) decreased systolic blood pressure by <20%, with minimal change in heart rate, whereas intracoronary adenosine had no effect on these parameters. FFR measurements with intracoronary nitroprusside were identical to those obtained with intracoronary adenosine (r=0.97). CONCLUSIONS: Compared with adenosine, intracoronary nitroprusside produces an equivalent but more prolonged coronary hyperemic response in normal coronary arteries. Intracoronary nitroprusside, in doses commonly used for the treatment of the no-reflow phenomenon, can produce sustained coronary hyperemia without detrimental systemic hemodynamics. On the basis of FFR measurements compared with adenosine, sodium nitroprusside also appears to be a suitable hyperemic stimulus for coronary physiological measurements.
Authors:
Walter A Parham; Andre Bouhasin; Jeffrey P Ciaramita; Souheil Khoukaz; Steven C Herrmann; Morton J Kern
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article     Date:  2004-03-01
Journal Detail:
Title:  Circulation     Volume:  109     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-03-16     Completed Date:  2004-06-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1236-43     Citation Subset:  AIM; IM    
Affiliation:
J. Gerard Mudd Cardiac Catheterization Laboratory, St Louis University Health Sciences Center, St Louis, Mo, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine / administration & dosage,  diagnostic use,  pharmacology
Adult
Aged
Blood Pressure / drug effects
Comorbidity
Coronary Angiography
Coronary Circulation / drug effects*
Coronary Disease / physiopathology*,  radiography
Coronary Stenosis / physiopathology,  radiography
Coronary Vessels
Female
Heart Catheterization*
Hemodynamics / drug effects
Humans
Hyperemia / chemically induced*
Injections, Intra-Arterial
Male
Middle Aged
Nitroprusside / administration & dosage,  diagnostic use,  pharmacology*
Risk Factors
Stroke Volume / drug effects
Vasodilator Agents / administration & dosage,  diagnostic use,  pharmacology*
Chemical
Reg. No./Substance:
0/Vasodilator Agents; 15078-28-1/Nitroprusside; 58-61-7/Adenosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes.
Next Document:  Does breast-feeding in infancy lower blood pressure in childhood? The Avon Longitudinal Study of Par...